AstraZeneca: successfully completes acquisition of Icosavax
Following this acquisition, Icosavax becomes a subsidiary of AstraZeneca, with operations in Seattle, USA.
The acquisition will strengthen AstraZeneca's pipeline, including IVX-12, Icosavax's lead investigational vaccine candidate (ready for phase III) against RSV and human metapneumovirus (hMPV).
The acquisition was effected by way of a tender offer to purchase all outstanding shares of Icosavax for an initial price of $15 per share, plus a contingent value right of up to $5 per share.
Together, the initial and contingent value rights payments, if realized, represent a transaction value of approximately $1.1 billion.
At the expiry of the tender offer, 35,912,932 representing approximately 70.7% of Icosavax's outstanding common shares had been tendered.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction